Sun Pharmaceutical Industries Limited (SUNPHARMA) Net Income 2023–2026

Name: Sun Pharmaceutical Industries Limited (SUNPHARMA) net income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Sun Pharmaceutical Industries Limited annual net income for fiscal 2026 was ₹114.8 billion, an increase of 5.0% from ₹109.3 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

SUNPHARMA Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Net Income	₹114.8B	₹109.3B	₹95.8B	₹84.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUNPHARMA Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Net Income	₹28.9B	₹27.1B	₹33.7B	₹22.8B	₹21.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4502 Net Income — Takeda Pharmaceutical Company Limited
4507 Net Income — Shionogi & Co., Ltd.
DIVISLAB Net Income — Divi's Laboratories Limited
TORNTPHARM Net Income — Torrent Pharmaceuticals Limited
4523 Net Income — Eisai Co., Ltd.
4151 Net Income — Kyowa Kirin Co., Ltd.

More SUNPHARMA metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All SUNPHARMA financial statements → Interactive SUNPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.